Navigation Links
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
Date:10/6/2009

TOKYO, Oct. 6 /PRNewswire/ -- R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness) (Note 1).

Phase I clinical trial in healthy male volunteers that began in 2008 demonstrated the safety of RK-023 (Note 2). Early phase II clinical trial has been started for two purposes. One is to evaluate the safety of RK-023 for long-term use by men with pattern baldness. The other is to examine the preliminary effectiveness of this compound on hair growing. This clinical trial will be a double blind (Note 3), placebo-controlled (Note 4) study in which the study drug is applied to the scalp for 13 consecutive weeks.

"I am very pleased that early phase II clinical trial for RK-023 has started," said Dr. Yukihiko Mashima, president of R-Tech Ueno. "This is a compound that we are developing on our own for the treatment of male pattern baldness, which is part of our core dermatology operations. We plan to proceed with development activities quickly while conducting negotiations concerning alliances with companies in Japan and overseas."

R-Tech Ueno determines to complete the development of RK-023, quickly in order to provide assistance as soon as possible to men who are troubled by the loss of hair.

Notes:

  1. Androgenetic alopecia (male pattern baldness) is also called common baldness with aging. Following puberty, male hormones can prevent the regeneration of thick, long hair starting at the top of the skull and spreading forward. This hair is gradually replaced with thin, short hair. Eventually, this process leads to the atrophy of hair follicles and a decline in the number of strands of hair. Men first experience thinning of their hair and then baldness. This condition affects about 12 million men in Japan.
  2. See the R-Tech Ueno press release related July 16, 2009 for more information about the Phase I clinical trial.
  3. In a double-blind test, for the purpose of conducting the clinical trial in a completely objective manner, the physicians performing the trial as well as the patients participating in the trial do not know if the substance administered to each individual is the drug being tested or the placebo.
  4. The placebo is a substance that does not include the drug being tested (RK-023 in this case).

About R-Tech Ueno, Ltd.

R-Tech Ueno was established in September 1989 for the purpose of marketing and R&D of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme "Physician-Oriented New Drug Innovation," targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent. The company's main product Rescula(R) eyedrop 0.12% is a therapeutic drug for glaucoma and ocular hypertension and has been marketed in Japan since 1994. R-Tech Ueno was the first in the world to take advantage of the substance "prostone" in the development of Rescula(R). Prostone was discovered in 1980 by Dr. Ryuji Ueno, the founder of the company. Rescula(R) eyedrop 0.12% that causes less topical and systemic adverse reactions demonstrates steady ocular pressure-decreasing action by twice-a-day instillation. Such excellent therapeutic effects are realized through its optic nerve protection and ocular blood flow-increasing mechanism.

    Stock Code: No.4573, Osaka Securities Exchange; Hercules
    Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
    Representative Director & President: Yukihiko Mashima


    Contact:
    Koji Nakamura,
    Business Management Department
    R-Tech Ueno, Ltd.
    Tel: +81-3-3596-8011
    e-mail: koji.nakamura@rtueno.co.jp
    URL: http://rtechueno.com/en/

SOURCE R-Tech Ueno, Ltd.


'/>"/>
SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
4. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
5. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
6. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
7. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
8. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
9. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
10. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 27, 2016   Zillion Group today ... technology platform, which specializes in live video consultation. ... digital products, Zillion enables companies to realize the ... to take control of their health. ... – including one-to-one, group and webcast scheduled or ...
(Date:4/27/2016)...  Bayer Animal Health today announced that ... of Florida College of Veterinary Medicine, is the ... Award (BECA). Brittany was selected from entries representing ... of $70,000 in scholarship funds through the 2016 ... provided a total of $232,500 in scholarship awards ...
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... The number of chronically and ... – meaning that there is an urgent need for highly skilled care managers and ... delivering a multi-pronged approach to train and retain care managers, and enhance their skills. ...
(Date:4/28/2016)... ... April 28, 2016 , ... The Dentists ... it has signed a letter of intent with Moda to acquire ... Company (NORDIC). , Started by dentists 36 years ago, TDIC focuses exclusively on ...
(Date:4/28/2016)... ... ... Head Over Heels Athletic Arts’ gymnast, Brooklyn Varize, has qualified to compete in ... University of Montana on April 28-May 1. Varize will compete on Saturday against the ... qualify, Varize needed to place top seven all-around in her respective age group. Varize ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... the Campaign for Tobacco-Free Kids, a leading force in the fight to reduce ... state and local policies that can help reduce tobacco use. The initiative brings ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... solutions, announces today the availability of its latest software release, NetZoomDC 14.5. ... management and optimization, providing new analytical capabilities that assess complex capacity factors ...
Breaking Medicine News(10 mins):